Bispecific Antibodies in Hematological Malignancies: Teclistamab, Mosunetuzumab & Epcoritamab FDA Review

Key Takeaways

• Regulatory momentum: The U.S. Food and Drug Administration (FDA) has granted 7 approvals for bispecific antibodies in hematological malignancies, including teclistamab, mosunetuzumab, and epcoritamab, reflecting accelerated regulatory pathways for this emerging drug class.
• Clinical efficacy: CD3-targeting bispecific antibodies have demonstrated durable responses in multiple myeloma and B-cell lymphomas, with efficacy extending beyond relapsed/refractory settings into earlier treatment lines.
• Market reshaping: Rapid FDA approvals and expanding label indications are intensifying competition with CAR-T cell therapies and monoclonal antibodies, shifting standard care protocols in hematological malignancies. [Source: U.S. Food and Drug Administration]
• Next steps: Ongoing clinical development focuses on combination strategies, earlier-line applications, and management of cytokine release syndrome to optimize patient outcomes and broaden adoption.

The FDA has approved a new class of immunotherapeutic agents—bispecific antibodies—that engage T cells and tumor antigens simultaneously to treat hematological malignancies. Teclistamab, mosunetuzumab, and epcoritamab represent the vanguard of this therapeutic approach, with seven FDA approvals across the class to date. Why it matters: These agents address a critical unmet need by delivering durable responses in relapsed/refractory multiple myeloma and B-cell lymphomas, while demonstrating safety profiles that enable expansion into earlier treatment lines—a shift that could fundamentally alter oncology practice patterns.

Drug Overview

Bispecific antibodies (BsAbs) represent a distinct monoclonal antibody class engineered to simultaneously bind two different antigens. Teclistamab, mosunetuzumab, and epcoritamab are CD3-targeting bispecific antibodies that engage CD3 on T cells and tumor-associated antigens on malignant cells, thereby redirecting T cell cytotoxicity against cancer cells. These agents differ from conventional monoclonal antibodies and CAR-T cell therapies by combining the precision of targeted binding with the inherent immunological potency of T cell engagement.

Teclistamab targets BCMA (B-cell maturation antigen) on malignant plasma cells and is indicated for multiple myeloma. Mosunetuzumab and epcoritamab target CD20 on B-cell malignancies, addressing diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The mechanism of action—bridging T cells to tumor cells—enables sustained anti-tumor activity while potentially offering advantages over CAR-T approaches in terms of manufacturing scalability and reduced off-target toxicity.

Clinical Insights

Clinical trials of teclistamab in multiple myeloma have shown durable responses in patient populations previously limited to relapsed/refractory disease. These data have supported FDA approvals and label expansions beyond salvage-line settings, demonstrating that the bispecific antibody mechanism can sustain long-term disease control. Specific trial names, enrollment numbers, and exact response rates were not disclosed in available regulatory documentation; however, the durability of responses observed has been a key driver of regulatory and clinical confidence.

Mosunetuzumab and epcoritamab have demonstrated promising efficacy in B-cell lymphomas with manageable safety profiles. Both agents have advanced through clinical development in DLBCL and FL, with efficacy supporting their progression into earlier treatment lines. The safety profile across these bispecific antibodies generally shows manageable adverse events, though cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain considerations requiring clinical monitoring and management protocols.

Compared with CAR-T cell therapies, bispecific antibodies offer distinct advantages: they do not require patient leukapheresis and ex vivo manufacturing, enabling rapid deployment in clinical settings. However, the exact comparative efficacy data between these modalities remains an active area of clinical investigation, with ongoing trials designed to establish optimal sequencing and combination strategies.

Regulatory Context

The FDA has granted 7 approvals for bispecific antibodies in hematological malignancies to date, representing unprecedented regulatory momentum for this emerging drug class. These approvals reflect the FDA's commitment to expedited review pathways, including Breakthrough Therapy Designation (BTD) and Priority Review, which have accelerated the development timelines for teclistamab, mosunetuzumab, and epcoritamab.

The regulatory pathway for bispecific antibodies has evolved rapidly, with the FDA Oncology Center of Excellence (OCE) playing a central role in streamlining approval processes. Specific submission dates, PDUFA action dates, and whether individual approvals were granted as standard or accelerated reviews have not been uniformly disclosed; however, the cumulative trend of 7 approvals within a compressed timeframe underscores regulatory confidence in the class's clinical benefit and manageable risk profile.

Label indications have expanded progressively, reflecting clinical trial results supporting use in earlier treatment lines and broader patient populations. This iterative approach to approval and label expansion has enabled rapid translation of clinical evidence into patient access while maintaining regulatory oversight of safety and efficacy.

Market Impact

The rapid FDA approval of bispecific antibodies is reshaping the competitive landscape in hematological malignancies. Teclistamab competes directly with CAR-T cell therapies and other monoclonal antibodies in multiple myeloma, while mosunetuzumab and epcoritamab address similar competitive spaces in B-cell lymphomas. The shift toward earlier-line applications expands the addressable patient population and intensifies competition for market share.

Unmet clinical needs have driven adoption of bispecific antibodies, particularly in patients who have exhausted or are ineligible for CAR-T therapy. The manufacturing advantages and rapid deployment of bispecific antibodies relative to cell therapies position them as complementary or alternative options in treatment algorithms. Pricing pressures in the U.S. healthcare system remain a critical consideration, with payers evaluating cost-effectiveness relative to competing immunotherapies.

The expansion of bispecific antibodies into earlier treatment lines—a key clinical trend—has direct market implications. Larger patient populations at earlier disease stages translate to higher treatment volumes and revenue potential, attracting sustained investment and competitive development efforts from multiple biopharmaceutical companies.

Future Outlook

The clinical development pipeline for bispecific antibodies continues to expand, with emerging candidates targeting novel antigens beyond BCMA and CD20. Combination strategies pairing bispecific antibodies with checkpoint inhibitors, proteasome inhibitors, and other modalities are under active investigation, with the goal of enhancing durability and overcoming resistance mechanisms.

What to watch next: Upcoming clinical trials will focus on optimal sequencing of bispecific antibodies with established therapies, management strategies for CRS and ICANS, and potential label expansions into frontline settings for both multiple myeloma and B-cell lymphomas. Regulatory guidance updates from the FDA regarding bispecific antibody development, including endpoints and trial design, are anticipated as the class matures.

Long-term challenges include the emergence of resistance mechanisms, optimization of patient selection, and integration of bispecific antibodies into existing treatment paradigms. The potential for combination therapies and the expanding clinical data set will likely drive further regulatory approvals and label changes, solidifying the role of bispecific antibodies as foundational agents in hematological oncology.

Frequently Asked Questions

References

1. U.S. Food and Drug Administration (FDA). Bispecific Antibody Approvals in Hematological Malignancies. FDA Oncology Center of Excellence, 2024–2025.

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-05-01.